Guidelines
Expert Recommendations on Supervision System for Microbiota Transplantation Technology: Dual-Track Regulatory Governance Framework
Zhi Guo1,2,#,*, Xiaochen Xiang2,#, Xiaohua Tan3, Hua Ren4, Mingqiang Qiao5, Jing Liang6, Xiaoan Li7, Qiang Wang2,*
1Department of Hematology, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen 518052, China. 2Institute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Medical College, Wuhan University of Science and Technology, Wuhan 430065, China. 3Department of Oncology, Qingdao Eighth People’s Hospital, Shandong Second Medical University, Qingdao 266121, China. 4School of Medicine, Southern University of Science & Technology, Shenzhen 518055, China. 5College of Life Sciences, Nankai University, Tianjin 300071, China. 6Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan 250014, China. 7NHC Key Laboratory of Nuclear Technology Medical Transformation (Mianyang Central Hospital), Mianyang 621000, China.
#, Authors contributed equally. *, Correspondence Professor Zhi Guo, PhD, Department of Hematology, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen 518052, China. E-mail: guozhi77@126.com. Professor Qiang Wang, PhD, Institute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Medical College, Wuhan University of Science and Technology, Wuhan 430065, China. E-mail: wangqiang@wust.edu.cn. Received: July 8, 2026. Accepted: August 28, 2026. Published online: November 16, 2026. Cite this paper: Zhi Guo, Xiaochen Xiang, Xiaohua Tan, Hua Ren, Mingqiang Qiao, Jing Liang, Xiaoan Li, Qiang Wang. Expert recommendations on supervision system for microbiota transplantation technology: Dual-track regulatory governance framework. Global Journal of Microbiology, 2026;7(2):1-7. http://naturescholars.com/gjmic.070201. https://doi.org/10.46633/gjmic.070201. Copyright © 2026 by Scholars Publishing, LLC.
Abstract
Microbiota transplantation represents a pivotal individualized therapeutic strategy for drug-resistant infections, inflammatory bowel diseases, and refractory chronic disorders. Nevertheless, the global uniformity of pharmaceutical-oriented supervision has long restricted the clinical translation and innovative development of microbiota transplantation technologies. China has established an innovative dual-track regulatory governance system for emerging biomedical technologies, which differentiates standardized mass-produced microbial preparations from highly individualized microbiota intervention techniques. This article elaborates the top-level institutional design of the dual-track framework, clarifies the regulatory boundary between routine clinical microbiota transplantation and innovative engineered microbial technologies, and interprets the exemption rules and hierarchical risk management mechanism for conventional fecal microbiota transplantation. Furthermore, it summarizes the differentiated supervision pathways, priority review strategies for unmet clinical needs, and existing implementation challenges.
Keywords
Microbial therapy; dual-track regulation; intestinal microbiota transplantation; live biotherapeutic products.